|

INBRX-106 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Hexavalent OX40 agonist antibody

Pipeline

Phase 2: 1Phase 2/3: 1

Top Sponsors

  • Providence Health & Services1
  • Inhibrx Biosciences, Inc1

Indications

  • Cancer2
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Triple Negative Breast Cancer1
  • Breast Cancer1

Duarte, California1 trial

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

City of Hope Medical Center

Phase 2/3

Los Angeles, California1 trial

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Ellison Institute of Technology (EITM)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.